首页> 外文期刊>Progress in Artificial Intelligence >Molecular docking and ADMET-based mining of terpenoids against targets of type-II diabetes
【24h】

Molecular docking and ADMET-based mining of terpenoids against targets of type-II diabetes

机译:分子对接和基于额外的三萜矿物抗吐药靶 - II型糖尿病靶标

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Despite the availability of various medicines for the treatment of diabetes, plant-based drugs draw special attention due to their low cost and lesser side effects. The rhizomes of plant Hedychium coronarium have been reported for its anti-diabetic activity previously. In the present study, docking and computational ADME parameters of a few terpenoid ligands isolated from the above-mentioned plant against two control molecules (Sitagliptin, Metformin) were compared. The retrieved docked images indicated the docking sites in the target protein. Out of the five compounds, Digoxigenin monodigitoxoside has shown the best docking result. The LD50 of this compound is very similar to control and lower than others. This in silico study confirmed that terpenoids present in the plant rhizome are a potent drug candidate for the treatment of type-II diabetes. We have identified a few best-fit terpenoid molecules against identified targets using in silico studies, which may give new drugs to combat type-II diabetes after wet-lab validation.
机译:尽管有各种药物治疗糖尿病,但植物的药物由于其低成本和较小的副作用而引起了特别的关注。据报道,植物Hedychium冠状癌的根茎以前据报道其抗糖尿病活性。在本研究中,比较了从上述植物中分离的少量萜类配体的对接和计算ADME参数,针对两种对照分子(SitaGliptin,二甲双胍)。检索到的对接图像指示目标蛋白质中的对接位点。在五种化合物中,Digoxigenin Monodigitoxoside已经显示出最佳的对接结果。该化合物的LD50与对照和低于其他化合物非常相似。这在硅研究中证实,植物根茎中存在的萜类化合物是治疗II型糖尿病的有效药物候选者。我们已经鉴定了在硅研究中使用的鉴定靶标的少量最合适的萜类分子,这可能会使新药能够在湿式实验室验证后打击II型糖尿病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号